Greenwich LifeSciences (GLSI) Financials

Greenwich LifeSciences logo
$13.76 -1.18 (-7.90%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$13.68 -0.08 (-0.58%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Greenwich LifeSciences

Annual Income Statements for Greenwich LifeSciences

This table shows Greenwich LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Consolidated Net Income / (Loss)
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Net Income / (Loss) Continuing Operations
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Total Pre-Tax Income
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Total Operating Income
-3.43 -1.86 -4.60 -8.04 -9.33 -18 -19
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
3.43 1.86 4.60 8.04 9.33 18 19
Selling, General & Admin Expense
0.82 0.81 1.04 1.56 1.63 2.16 2.23
Research & Development Expense
2.61 1.06 3.56 6.48 7.70 15 17
Total Other Income / (Expense), net
0.00 0.00 0.03 0.22 0.44 0.22 0.09
Interest & Investment Income
0.00 0.00 0.03 0.22 0.44 0.22 0.09
Basic Earnings per Share
($1.52) ($0.20) ($0.35) ($0.61) ($0.69) ($1.34) ($1.43)
Weighted Average Basic Shares Outstanding
2.26M 9.50M 12.94M 12.91M 12.85M 13.01M 13.53M
Diluted Earnings per Share
($1.52) ($0.20) - ($0.61) ($0.69) ($1.34) ($1.43)
Weighted Average Diluted Shares Outstanding
2.26M 9.50M 12.94M 12.91M 12.85M 13.01M 13.53M

Quarterly Income Statements for Greenwich LifeSciences

This table shows Greenwich LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-2.47 -2.61 -2.67 -8.04 -2.74 -3.75 -3.71 -7.92 -5.66 -3.95 -5.81
Consolidated Net Income / (Loss)
-2.47 -2.61 -2.67 -8.04 -2.74 -3.75 -3.71 -7.92 -5.66 -3.95 -5.81
Net Income / (Loss) Continuing Operations
-2.47 -2.61 -2.67 -8.04 -2.74 -3.75 -3.71 -7.92 -5.66 -3.95 -5.81
Total Pre-Tax Income
-2.47 -2.61 -2.67 -8.04 -2.74 -3.75 -3.71 -7.92 -5.66 -3.95 -5.81
Total Operating Income
-2.54 -2.66 -2.73 -8.08 -2.77 -3.77 -3.73 -7.94 -5.73 -4.02 -5.86
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
2.54 2.66 2.73 8.08 2.77 3.77 3.73 7.94 5.73 4.02 5.86
Selling, General & Admin Expense
0.34 0.35 0.44 1.93 0.50 0.35 0.47 0.36 0.52 0.46 0.41
Research & Development Expense
2.19 2.31 2.29 6.16 2.27 3.42 3.27 7.59 5.21 3.56 5.45
Total Other Income / (Expense), net
0.06 0.05 0.06 0.04 0.02 0.02 0.02 0.02 0.07 0.07 0.05
Interest & Investment Income
0.06 0.05 0.06 0.04 0.02 0.02 0.02 0.02 0.07 0.07 0.05
Basic Earnings per Share
($0.19) ($0.20) ($0.20) ($0.62) ($0.21) ($0.28) ($0.27) ($0.58) ($0.39) ($0.27) ($0.40)
Weighted Average Basic Shares Outstanding
12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M 14.62M 14.68M
Diluted Earnings per Share
($0.19) ($0.20) ($0.20) ($0.62) ($0.21) ($0.28) ($0.27) ($0.58) ($0.39) ($0.27) ($0.40)
Weighted Average Diluted Shares Outstanding
12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M 14.62M 14.68M
Weighted Average Basic & Diluted Shares Outstanding
12.88M 13.14M 13.14M 0.00 13.37M 13.63M 13.85M 0.00 14.68M 14.68M 14.68M

Annual Cash Flow Statements for Greenwich LifeSciences

This table details how cash moves in and out of Greenwich LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.08 29 -1.46 -14 -6.48 -2.90 2.09
Net Cash From Operating Activities
-0.29 -1.15 -4.29 -6.20 -6.48 -7.27 -9.91
Net Cash From Continuing Operating Activities
-0.29 -1.15 -4.29 -6.20 -6.48 -7.27 -9.91
Net Income / (Loss) Continuing Operations
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Consolidated Net Income / (Loss)
-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Amortization Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
2.69 0.68 0.66 1.74 2.38 7.25 6.80
Changes in Operating Assets and Liabilities, net
0.43 0.03 -0.39 -0.12 0.03 2.89 2.64
Net Cash From Investing Activities
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities
0.22 30 2.84 -7.54 0.00 4.37 12
Net Cash From Continuing Financing Activities
0.22 30 2.84 -7.54 0.00 4.37 12
Issuance of Common Equity
0.00 30 3.11 - 0.00 4.37 12
Other Financing Activities, net
- - - - - 0.00 0.15

Quarterly Cash Flow Statements for Greenwich LifeSciences

This table details how cash moves in and out of Greenwich LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.48 1.72 -1.40 -1.73 -1.34 0.38 0.68 2.37 4.33 -1.63 -2.98
Net Cash From Operating Activities
-1.78 -1.05 -2.58 -1.85 -1.83 -2.23 -2.67 -3.17 -4.70 -1.94 -2.98
Net Cash From Continuing Operating Activities
-1.78 -1.05 -2.58 -1.85 -1.83 -2.23 -2.67 -3.17 -4.70 -1.94 -2.98
Net Income / (Loss) Continuing Operations
-2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66 -3.95 -5.81
Consolidated Net Income / (Loss)
-2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66 -3.95 -5.81
Non-Cash Adjustments To Reconcile Net Income
0.59 0.59 0.59 5.47 1.54 1.54 1.54 2.17 1.54 1.48 0.95
Changes in Operating Assets and Liabilities, net
0.10 0.96 -0.51 0.72 -0.63 0.25 -0.06 2.58 -0.59 0.52 1.89

Annual Balance Sheets for Greenwich LifeSciences

This table presents Greenwich LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.03 29 27 13 6.99 4.09 6.18
Total Current Assets
0.01 29 27 13 6.99 4.09 6.18
Cash & Equivalents
0.01 29 27 13 6.99 4.09 6.18
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.02 0.02 0.01 0.01 0.01 0.00 0.00
Total Liabilities & Shareholders' Equity
0.03 29 27 13 6.99 4.09 6.18
Total Liabilities
1.38 1.05 0.39 0.26 0.29 3.19 5.82
Total Current Liabilities
1.38 1.05 0.39 0.26 0.29 3.19 5.82
Accounts Payable
1.37 0.99 0.22 0.22 0.26 2.80 4.87
Current Employee Benefit Liabilities
0.01 0.06 0.16 0.04 0.04 0.08 0.95
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-1.35 28 27 13 6.70 0.91 0.35
Total Preferred & Common Equity
-1.35 28 27 13 6.70 0.91 0.35
Total Common Equity
-1.35 28 27 13 6.70 0.91 0.35
Common Stock
26 57 60 55 57 69 87
Retained Earnings
-27 -29 -34 -41 -50 -68 -87

Quarterly Balance Sheets for Greenwich LifeSciences

This table presents Greenwich LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
9.15 5.51 7.23 5.83 2.75 3.13 3.81 11 8.88 5.90
Total Current Assets
9.14 5.51 7.22 5.82 2.75 3.13 3.81 11 8.88 5.90
Cash & Equivalents
9.14 5.51 7.22 5.82 2.75 3.13 3.81 11 8.88 5.90
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
9.15 5.51 7.23 5.83 2.75 3.13 3.81 11 8.88 5.90
Total Liabilities
0.30 0.39 1.35 0.84 1.44 1.69 1.62 5.24 5.76 7.65
Total Current Liabilities
0.30 0.39 1.35 0.84 1.44 1.69 1.62 5.24 5.76 7.65
Accounts Payable
0.23 0.35 1.34 0.77 1.05 1.30 1.11 4.51 5.03 6.90
Current Employee Benefit Liabilities
0.07 0.04 0.02 0.07 0.08 0.08 0.51 0.05 0.73 0.74
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27 3.12 -1.75
Total Preferred & Common Equity
8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27 3.12 -1.75
Total Common Equity
8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27 3.12 -1.75
Common Stock
56 58 61 63 71 75 80 98 100 101
Retained Earnings
-48 -53 -55 -58 -69 -73 -78 -93 -97 -103

Annual Metrics And Ratios for Greenwich LifeSciences

This table displays calculated financial ratios and metrics derived from Greenwich LifeSciences' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 12,019,089.00 13,123,377.00 12,848,165.00 12,848,165.00 - 13,854,539.00
DEI Adjusted Shares Outstanding
0.00 12,019,089.00 13,123,377.00 12,848,165.00 12,848,165.00 - 13,854,539.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.16 -0.35 -0.61 -0.69 - -1.40
Growth Metrics
- - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 45.64% -146.98% -74.93% -16.02% -71.68% -10.28%
EBIT Growth
0.00% 45.59% -146.70% -74.87% -16.01% -71.66% -10.27%
NOPAT Growth
0.00% 45.59% -146.70% -74.87% -16.01% -71.66% -10.27%
Net Income Growth
0.00% 45.61% -145.34% -71.21% -13.63% -77.57% -11.16%
EPS Growth
0.00% 86.84% 0.00% 0.00% -13.11% -75.36% -6.72%
Operating Cash Flow Growth
0.00% -293.14% -272.22% -44.47% -4.49% -12.16% -36.43%
Free Cash Flow Firm Growth
0.00% 0.00% -137.36% -48.30% -13.01% -53.04% -16.09%
Invested Capital Growth
0.00% 24.17% 63.80% 31.85% -13.83% -439.06% -82.98%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -36.37% -6.88% 0.63% -48.77% 0.71%
EBIT Q/Q Growth
0.00% 0.00% -36.33% -6.88% 0.62% -48.76% 0.71%
NOPAT Q/Q Growth
0.00% 0.00% -36.33% -6.88% 0.62% -48.76% 0.71%
Net Income Q/Q Growth
0.00% 0.00% -35.99% -5.81% 0.49% -50.44% 0.60%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -53.16% 2.72%
Operating Cash Flow Q/Q Growth
0.00% -438.35% -34.95% 1.50% 0.24% 3.99% -15.39%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -4.88% 0.20% -42.28% 15.13%
Invested Capital Q/Q Growth
0.00% 0.00% 15.63% -11.37% 0.68% -85.54% -259.11%
Profitability Metrics
- - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 99.96% 99.40% 97.33% 95.33% 98.61% 99.54%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
253.65% -14.18% -16.78% -39.08% -89.30% -341.95% -3,068.25%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
254.02% -14.18% -16.78% -39.08% -89.30% -341.95% -3,068.25%
Return on Equity Simple (ROE_SIMPLE)
253.65% -6.74% -17.03% -59.22% -132.71% -623.07% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.40 -1.30 -3.22 -5.63 -6.53 -11 -14
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-15,034.27% -3.90% -4.84% -10.80% -23.09% -82.67% -111.87%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -97.45% -442.31% -3,854.16%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.43 -1.86 -4.60 -8.04 -9.33 -16 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.42 -1.86 -4.59 -8.04 -9.32 -16 -19
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 15.86 11.90 14.78 20.17 58.25 824.09
Price to Tangible Book Value (P/TBV)
0.00 15.87 11.91 14.79 20.19 58.29 824.09
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.01 -1.09 -1.03 -1.02 -1.03 -1.20 -8.14
Leverage Ratio
-0.02 1.09 1.03 1.02 1.03 1.20 8.14
Compound Leverage Factor
-0.02 1.09 1.02 0.99 0.98 1.18 8.10
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
-0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.15% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-1,910.81 251.08 496.27 440.59 262.13 22.00 -0.08
Noncontrolling Interest Sharing Ratio
-0.15% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.01 27.41 70.63 51.23 23.74 2.62 1.06
Quick Ratio
0.01 27.41 70.63 51.23 23.74 2.62 1.06
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -1.63 -3.88 -5.75 -6.49 -9.94 -11
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - -
Invested Capital
-1.36 -1.03 -0.37 -0.25 -0.29 -1.56 -5.82
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 0.33 0.66 0.12 -0.04 -1.27 -2.64
Enterprise Value (EV)
7.25 410 292 182 128 144 285
Market Capitalization
7.25 438 319 195 135 148 291
Book Value per Share
($0.60) $2.30 $2.04 $1.03 $0.52 $0.19 $0.03
Tangible Book Value per Share
($0.61) $2.30 $2.04 $1.03 $0.52 $0.19 $0.03
Total Capital
-1.35 28 27 13 6.70 2.53 0.35
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-0.01 -29 -27 -13 -6.99 -4.09 -6.18
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.38 -1.05 -0.39 -0.26 -0.29 -1.56 -5.82
Debt-free Net Working Capital (DFNWC)
-1.37 28 27 13 6.70 2.53 0.35
Net Working Capital (NWC)
-1.37 28 27 13 6.70 2.53 0.35
Net Nonoperating Expense (NNE)
1.03 0.56 1.35 2.20 2.36 4.58 5.74
Net Nonoperating Obligations (NNO)
-0.01 -29 -27 -13 -6.99 -4.09 -6.18
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.20) ($0.35) ($0.61) ($0.69) ($1.21) ($1.43)
Adjusted Weighted Average Basic Shares Outstanding
0.00 12.85M 12.95M 12.91M 12.85M 13.01M 13.53M
Adjusted Diluted Earnings per Share
$0.00 ($0.20) ($0.35) $0.00 ($0.69) ($1.21) ($1.43)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 12.85M 12.95M 12.85M 12.85M 13.01M 13.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($0.20) ($0.35) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 9.50M 12.94M 12.85M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-2.40 -1.30 -3.22 -5.63 -6.53 -11 -14
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -96.31% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Greenwich LifeSciences

This table displays calculated financial ratios and metrics derived from Greenwich LifeSciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
12,848,165.00 12,879,995.00 13,144,653.00 - 13,144,653.00 13,368,304.00 13,630,257.00 13,854,539.00 13,854,539.00 29,356,416.00 14,678,208.00
DEI Adjusted Shares Outstanding
12,848,165.00 12,879,995.00 13,144,653.00 - 13,144,653.00 13,368,304.00 13,630,257.00 13,854,539.00 13,854,539.00 29,356,416.00 14,678,208.00
DEI Earnings Per Adjusted Shares Outstanding
-0.19 -0.20 -0.20 - -0.21 -0.30 -0.30 -0.57 -0.41 -0.13 -0.40
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-13.22% -52.30% -9.04% -185.11% -9.13% -52.04% -53.02% 18.17% -106.87% -6.72% -56.95%
EBIT Growth
-13.21% -52.27% -9.03% -185.05% -9.13% -52.02% -52.97% 18.17% -106.80% -6.69% -56.95%
NOPAT Growth
-13.21% -52.27% -9.03% -185.05% -9.13% -52.02% -52.97% 18.17% -106.80% -6.69% -56.95%
Net Income Growth
-16.39% -60.08% -11.58% -192.72% -10.98% -54.42% -55.57% 18.03% -106.11% -5.34% -56.65%
EPS Growth
-11.76% -53.85% -5.26% -210.00% -10.53% -50.00% -50.00% 22.67% -85.71% 3.57% -48.15%
Operating Cash Flow Growth
-14.50% -8.36% -43.50% 14.02% -2.91% -113.11% -3.38% -71.40% -156.34% 13.14% -11.48%
Free Cash Flow Firm Growth
-3.03% 29.59% 19.38% -125.11% 45.28% -208.95% -57.16% 25.17% 76.24% 154.67% 204.89%
Invested Capital Growth
-69.30% -358.45% -188.56% -439.06% -273.30% -24.91% -93.16% -82.98% -264.15% -241.68% -371.36%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
10.54% -4.90% -2.54% -196.29% 71.49% -23.27% -3.20% -90.32% 27.93% 29.76% -45.72%
EBIT Q/Q Growth
10.54% -4.90% -2.54% -196.23% 71.48% -23.26% -3.18% -90.32% 27.93% 29.76% -45.72%
NOPAT Q/Q Growth
10.54% -4.90% -2.54% -196.23% 71.48% -23.26% -3.18% -90.32% 27.93% 29.76% -45.72%
Net Income Q/Q Growth
9.96% -5.40% -2.38% -201.28% 71.60% -23.54% -3.14% -90.82% 28.60% 30.20% -47.23%
EPS Q/Q Growth
5.00% -5.26% 0.00% -210.00% 72.00% -20.00% 0.00% -93.33% 32.76% 30.77% -48.15%
Operating Cash Flow Q/Q Growth
17.25% 41.22% -146.60% 28.32% 0.96% -21.73% -19.62% -18.85% -48.13% 58.75% -53.51%
Free Cash Flow Firm Q/Q Growth
17.01% 50.08% -68.54% -222.41% 77.31% -100.46% 14.26% -36.45% 92.79% 698.08% 52.63%
Invested Capital Q/Q Growth
-33.25% -250.39% 37.77% -85.54% 54.84% -17.25% 3.77% -259.11% 10.12% -10.01% -32.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
97.48% 97.94% 97.79% 99.46% 99.13% 99.49% 99.45% 99.72% 98.80% 98.19% 99.20%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-109.97% -123.67% -151.72% -341.95% -549.83% -491.94% -543.43% -3,068.25% -676.66% -986.32% -11,218.11%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-109.97% -123.67% -151.72% -341.95% -549.83% -491.94% -543.43% -3,068.25% -676.66% -986.32% -11,218.11%
Return on Equity Simple (ROE_SIMPLE)
-180.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.78 -1.86 -1.91 -5.66 -1.94 -2.83 -2.92 -5.56 -4.01 -2.82 -4.10
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.01% -8.19% -10.13% -42.98% -19.54% -23.06% -25.54% -45.98% -24.88% -18.89% -35.26%
Return On Investment Capital (ROIC_SIMPLE)
-34.68% -31.71% -38.34% -223.32% -147.69% -196.75% -133.74% -1,574.53% -76.05% -90.32% 234.84%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.54 -2.66 -2.73 -8.08 -2.77 -4.05 -4.17 -7.94 -5.73 -4.02 -5.86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.54 -2.66 -2.73 -8.08 -2.77 -4.05 -4.17 -7.94 -5.73 -4.02 -5.86
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
50.03 37.84 37.91 58.25 95.56 84.23 62.07 824.09 63.14 110.48 0.00
Price to Tangible Book Value (P/TBV)
50.07 37.86 37.93 58.29 95.62 84.23 62.07 824.09 63.14 110.48 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.04 -1.10 -1.08 -1.20 -1.28 -1.41 -1.34 -8.14 -2.01 -2.63 -22.15
Leverage Ratio
1.04 1.10 1.08 1.20 1.28 1.42 1.34 8.14 2.01 2.63 22.15
Compound Leverage Factor
1.01 1.08 1.06 1.19 1.27 1.41 1.34 8.12 1.99 2.59 21.98
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
380.71 87.60 120.05 28.39 14.23 6.54 18.71 6.06 24.58 19.54 -7.18
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
14.13 5.34 6.91 2.62 1.91 1.85 2.35 1.06 2.01 1.54 0.77
Quick Ratio
14.13 5.34 6.91 2.62 1.91 1.85 2.35 1.06 2.01 1.54 0.77
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1.62 -0.81 -1.36 -4.39 -0.89 -2.50 -2.14 -2.92 -0.21 1.26 1.92
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.39 -1.35 -0.84 -1.56 -1.44 -1.69 -1.62 -5.82 -5.24 -5.76 -7.65
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.16 -1.06 -0.55 -1.27 -1.05 -0.34 -0.78 -2.64 -3.80 -4.07 -6.02
Enterprise Value (EV)
251 215 183 144 123 118 132 285 322 335 259
Market Capitalization
256 222 189 148 125 121 136 291 333 344 265
Book Value per Share
$0.40 $0.46 $0.38 $0.19 $0.10 $0.11 $0.16 $0.03 $0.38 $0.21 ($0.12)
Tangible Book Value per Share
$0.40 $0.46 $0.38 $0.19 $0.10 $0.11 $0.16 $0.03 $0.38 $0.21 ($0.12)
Total Capital
5.12 5.88 4.98 2.53 1.31 1.44 2.18 0.35 5.27 3.12 -1.75
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-5.51 -7.22 -5.82 -4.09 -2.75 -3.13 -3.81 -6.18 -11 -8.88 -5.90
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.39 -1.35 -0.84 -1.56 -1.44 -1.69 -1.62 -5.82 -5.24 -5.76 -7.65
Debt-free Net Working Capital (DFNWC)
5.12 5.87 4.98 2.53 1.31 1.44 2.18 0.35 5.27 3.12 -1.75
Net Working Capital (NWC)
5.12 5.87 4.98 2.53 1.31 1.44 2.18 0.35 5.27 3.12 -1.75
Net Nonoperating Expense (NNE)
0.70 0.74 0.76 2.38 0.81 1.19 1.23 2.36 1.65 1.13 1.71
Net Nonoperating Obligations (NNO)
-5.51 -7.22 -5.82 -4.09 -2.75 -3.13 -3.81 -6.18 -11 -8.88 -5.90
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.19) ($0.20) ($0.20) ($0.62) ($0.25) ($0.30) ($0.30) ($0.58) ($0.39) ($0.27) ($0.40)
Adjusted Weighted Average Basic Shares Outstanding
12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M 14.62M 14.68M
Adjusted Diluted Earnings per Share
($0.19) ($0.20) ($0.20) ($0.62) ($0.25) ($0.30) ($0.30) ($0.58) ($0.39) ($0.27) ($0.40)
Adjusted Weighted Average Diluted Shares Outstanding
12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M 14.62M 14.68M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.88M 13.14M 13.14M 0.00 13.37M 13.63M 13.85M 0.00 14.68M 14.68M 14.68M
Normalized Net Operating Profit after Tax (NOPAT)
-1.78 -1.86 -1.91 -5.66 -1.94 -2.83 -2.92 -5.56 -4.01 -2.82 -4.10
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Greenwich LifeSciences remains a pre-revenue biotechnology company. The financial statements show no operating revenue in any of the reported quarters, while research and development spending continues to drive substantial losses. The company’s financial position has been supported primarily by common-stock issuances rather than internally generated cash.

Recent performance improved sequentially in some areas. In Q2 2026, operating expenses fell to $4.0 million from $5.7 million in Q1 2026 and $7.9 million in Q4 2025. The net loss narrowed to $3.9 million, or $0.27 per share, compared with a $5.7 million loss, or $0.39 per share, in Q1. Research and development expense also declined to $3.6 million from $5.2 million in the prior quarter.

  • Operating cash burn improved sequentially: net cash used in operating activities was $1.9 million in Q2 2026, down from $4.7 million in Q1 2026 and $3.2 million in Q4 2025.
  • Cash reserves remain meaningful: Greenwich LifeSciences held $8.9 million in cash and equivalents at June 30, 2026, despite reporting a $1.6 million quarterly decline in cash.
  • No noncurrent liabilities were reported: the company’s obligations were classified as current, with no long-term debt or other noncurrent liabilities shown on the balance sheet.
  • Sequential expense reduction: total operating expenses declined approximately 30% from Q1 2026, led by lower research and development spending.
  • Investment income provides a modest offset: interest and investment income increased to $73,000 in Q2 2026 from $69,000 in Q1, although it remains small relative to operating costs.

The company’s cash position has fluctuated considerably. Cash increased from $2.7 million at March 31, 2025, to $10.5 million at March 31, 2026, largely because of equity financing. It subsequently declined to $8.9 million by June 30, 2026. Based only on Q2’s operating cash burn, the ending cash balance represents roughly four to five quarters of operating funding, but actual runway could change materially as clinical and research spending fluctuates.

  • Liquidity is concentrated in cash: total current assets were $8.9 million, with no property, plant and equipment and no material noncurrent assets reported.
  • Equity financing remains central to the business model: the company raised $9.0 million through common-stock issuance in Q1 2026 and another $311,000 in Q2.
  • Current assets exceeded current liabilities: the company reported $8.9 million of current assets against $5.8 million of current liabilities, although much of the liability balance consisted of accounts payable.

Despite the recent improvement, the longer-term trend remains challenging. Greenwich LifeSciences has generated no revenue across the presented periods, and retained earnings were negative $96.7 million at June 30, 2026. Accounts payable increased to $5.0 million from $1.1 million in Q3 2025, while total current liabilities reached $5.8 million. This suggests that a significant portion of the company’s available cash is needed to fund accumulated obligations and ongoing research activities.

  • No commercial revenue has been reported: every presented income statement shows zero operating revenue, leaving the company dependent on financing and cash reserves.
  • Persistent net losses continue: Q2 2026 produced a $3.9 million net loss, following losses of $5.7 million in Q1 2026 and $7.9 million in Q4 2025.
  • Research spending remains high: R&D expense was $3.6 million in Q2 2026 and has generally increased from approximately $2.2 million per quarter in early 2024.
  • Operating cash flow remains negative: the company has not demonstrated the ability to fund operations internally, with negative operating cash flow in every listed cash-flow period.
  • Shareholder dilution is a continuing risk: weighted-average basic shares increased from 12.9 million in Q1 2024 to 14.6 million in Q2 2026, an increase of roughly 14%.
  • Accumulated deficits are substantial: negative retained earnings of $96.7 million exceeded the company’s $99.9 million common-stock balance, leaving total common equity at only $3.1 million.

Overall, the Q2 2026 statements show better cost control and a lower quarterly cash burn, but these improvements do not yet represent a change in the company’s underlying investment profile. Greenwich LifeSciences remains a development-stage biotechnology company with no revenue, recurring losses, ongoing clinical spending and likely future dependence on additional capital raises. Investors should closely monitor cash burn, accounts payable, clinical-development expenses and the terms of any future equity financing.

11/17/26 04:17 AM ETAI Generated. May Contain Errors.

Greenwich LifeSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Greenwich LifeSciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Greenwich LifeSciences' net income appears to be on a downward trend, with a most recent value of -$19.36 million in 2025, falling from -$3.43 million in 2019. The previous period was -$17.41 million in 2024. View Greenwich LifeSciences' forecast to see where analysts expect Greenwich LifeSciences to go next.

Greenwich LifeSciences' total operating income in 2025 was -$19.45 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $19.45 million

Over the last 6 years, Greenwich LifeSciences' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Greenwich LifeSciences' cash and equivalents has ranged from $2.75 million in Q1 2025 to $10.51 million in Q1 2026, and is currently $5.90 million as of their latest financial filing in Q3 2026.

Greenwich LifeSciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Greenwich LifeSciences' book value per share changed from -0.60 in 2019 to 0.03 in 2025.



Financial statements for NASDAQ:GLSI last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners